By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seikagaku Corporation 

1-5 Nihonbashi-honcho, 2-chome

Chuo-ku  Tokyo  103-0023  Japan
Phone: 81-3-3270-0966 Fax: 81-3-3270-0538



Company News
Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, Is to Commence Phase I Clinical Trial in Japan With CF101 for the Treatment of Rheumatoid Arthritis 8/18/2008 8:46:37 AM
Can-Fite BioPharma Progresses Through Clinical Trials: Completed Enrollment Of Half The Patients Required For Phase IIb RA Trial And Is Scheduled To Receive Next Payment Fom The Japanese Seikagaku Corporation 10/23/2006 10:59:23 AM
Seikagaku Corporation Obtains Sales Distribution Approval For MukoUp 10/20/2006 12:44:07 PM
Can-Fite BioPharma Out Licenses Rights For Its Drug, CF101, In Japan To The Seikagaku Corporation And Expects To Receive US$ 19.5 Million From Licensing Fees And Milestone Payments And Collect Substantial Royalties 9/25/2006 10:26:52 AM
Seikagaku Corporation To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatment In US 7/20/2006 7:34:29 PM
Discovery Partners International Inc. (DPII) Announces Receipt Of Success Milestone Payment In Its Lead Finding Collaboration With Seikagaku Corporation 11/9/2005 10:46:51 AM